COMBINING INNOVATIVE BIOMARKERS WITH OUTSTANDING TECHNOLOGY
Sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology.
Endothelial disruption: Rapid translation from bench to bedside.
Sphingotec raises €20 million from HBM and Wellington Partners.
Sphingotec is adding an advanced POC testing platform to portfolio